Regadenoson

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease, Myocardial Ischemia

Trial Timeline

Jan 1, 2010 → Mar 1, 2012

NCT ID

NCT01021618

About Regadenoson

Regadenoson is a pre-clinical stage product being developed by Astellas Pharma for Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01021618. Target conditions include Coronary Artery Disease, Myocardial Ischemia.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (2) Active (0)

✅EvolocumabHeartFlowApproved

✅Clopidogrel treatment groupYuhanApproved

✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved

✅statins, ezetimibe + Combination therapyYuhanApproved

✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved

✅PrasugrelDaiichi SankyoApproved

✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02697877	Pre-clinical	Completed	Feb 1, 2016	Jul 1, 2018	Coronary Artery Disease
NCT02589977	Approved	Completed	Nov 1, 2015	Jan 21, 2020	Heart Failure, Diastolic
NCT02220634	Pre-clinical	Terminated	Aug 1, 2014	May 25, 2017	Pulmonary Hypertension
NCT01969916	Pre-clinical	Completed	Jun 1, 2014	Jun 1, 2018	Coronary Artery Disease
NCT01779869	Approved	Completed	Jan 1, 2013	Jun 1, 2015	Ischemic Heart Disease
NCT01618669	Phase 3	Completed	Jun 1, 2012	Dec 1, 2014	Coronary Artery Disease (CAD)
NCT01446094	Approved	UNKNOWN	Aug 1, 2011	Jun 1, 2018	Coronary Artery Disease
NCT01334918	Phase 2	Completed	Apr 26, 2011	Jul 2, 2012	Coronary Artery Disease (CAD)
NCT01021618	Pre-clinical	Completed	Jan 1, 2010	Mar 1, 2012	Coronary Artery Disease
NCT01026012	Pre-clinical	Completed	Dec 1, 2009	Sep 1, 2010	Cardiac Function
NCT00881218	Phase 1	Completed	Jun 1, 2009	Dec 1, 2011	Ischemic Heart Disease
NCT00837369	Phase 1	Completed	Apr 7, 2009	Dec 1, 2011	Coronary Artery Disease
NCT00871260	Approved	Completed	Apr 1, 2009	Jun 4, 2014	Coronary Disease
NCT00857792	Pre-clinical	Completed	Mar 1, 2009	Jan 1, 2013	Coronary Disease

Competing Products

20 competing products in Coronary Artery Disease

See all competitors

Product	Company	Stage	Hype Score
Rosuvastatin 40mg + Placebo	HeartFlow	Pre-clinical	27
Evolocumab	HeartFlow	Approved	29
High intensity lipid lowering	HeartFlow	Pre-clinical	20
Exenatide	Eli Lilly	Phase 3	40
Clopidogrel treatment group	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe	Yuhan	Approved	43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)	Yuhan	Phase 3	40
statins, ezetimibe + Combination therapy	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel	Daiichi Sankyo	Approved	43
clopidogrel + prasugrel	Daiichi Sankyo	Phase 1	21
Prasugrel	Daiichi Sankyo	Approved	43
ADP receptor inhibitors	Daiichi Sankyo	Pre-clinical	26
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 2	35
prasugrel + clopidogrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Clopidogrel	Daiichi Sankyo	Approved	43
Triple oral lipid lowering treatment	Daiichi Sankyo	Phase 3	47
Placebo + Prasugrel	Daiichi Sankyo	Phase 3	40